Drug Profile
AZD 8055
Alternative Names: AZD-8055Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 08 Apr 2022 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 16 Nov 2011 Adverse events, pharmacokinetics & efficacy data from a phase I/II trial in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- 28 Jul 2011 Discontinued - Phase-I for Solid tumours in Japan (PO)